Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
28 nov. 2023 10h00 HE | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that...
Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
12 oct. 2022 10h00 HE | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
Kura Oncology Logo
Kura Oncology Appoints Carol Schafer to Board of Directors
04 juin 2021 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
08 déc. 2019 12h00 HE | Kura Oncology, Inc.
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients...
Kura Oncology Logo
Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
16 oct. 2019 16h30 HE | Kura Oncology, Inc.
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
16 sept. 2019 07h30 HE | Kura Oncology, Inc.
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 ...
Kura Oncology Logo
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma
03 sept. 2019 07h30 HE | Kura Oncology, Inc.
– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater...
Kura Oncology Logo
Kura Oncology to Participate in Two Upcoming Investor Conferences
29 août 2019 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
11 juil. 2019 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
21 juin 2019 16h30 HE | Kura Oncology, Inc.
SAN DIEGO, June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...